Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.63 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6827224 | 1.00 | HTT (0.63) | HTTFOLH1TGM2MMP2MMP9 | |
| SCHEMBL318935 | 1.00 | HTT (0.63) | HTTFOLH1TGM2MMP2MMP9 | |
| SCHEMBL6827180 | 0.99 | TGM2 (0.62) | HTTFOLH1TGM2MMP2MMP9 | |
| SCHEMBL6827355 | 0.99 | TGM2 (0.62) | HTTFOLH1TGM2MMP2MMP9 | |
| SCHEMBL6827174 | 0.99 | TGM2 (0.62) | HTTFOLH1TGM2MMP2MMP9 | |
| SCHEMBL2139878 | 0.96 | HTT (0.65) | HTTFOLH1TGM2MMP2MMP9 | |
| SCHEMBL2139876 | 0.96 | HTT (0.65) | HTTFOLH1TGM2MMP2MMP9 | |
| SCHEMBL11317170 | 0.96 | HTT (0.65) | HTTFOLH1TGM2MMP2MMP9 | |
| SCHEMBL6829468 | 0.90 | TGM2 (0.62) | HTTFOLH1TGM2MMP2MMP9 | |
| SCHEMBL334926 | 0.90 | SLC1A3 (0.64) | HTTFOLH1TGM2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152653-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | MEIJI SEIKA PHARMA CO LTD (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260465-B2 | Aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| CN-102942603-B | New aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-20 | — | — | CN | disclosed |
| EP-2036917-B1 | NOVEL AMINOGLYCOSIDE ANTIBIOTIC | MEIJI SEIKA PHARMA CO LTD (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20130345411-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2013-12-26 | — | — | US | disclosed |
| US-8541394-B2 | Aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2013-09-24 | — | — | US | disclosed |
| CN-102942603-A | Novel aminoglycoside antibiotics | MEIJI SEIKA KAISHA (JP) | 2013-02-27 | — | — | CN | disclosed |
| CN-101495493-B | Novel aminoglycoside antibiotics | MEIJI SEIKA KAISHA (JP) | 2012-11-14 | — | — | CN | disclosed |
| US-20120165283-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | KOBAYASHI YOSHIHIKO (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8148504-B2 | Aminoglycoside antibiotics | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-0249445-A2 | Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting enzyme inhibitors | E.R. Squibb & Sons, Inc. (US) | 1987-12-16 | — | — | EP | disclosed |
| US-4703043-A | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive | E. R. SQUIBB & SONS, INC. (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0239109-A2 | Phosphonate angiotensin converting enzyme inhibitors | E.R. Squibb & Sons, Inc. (US) | 1987-09-30 | — | — | EP | disclosed |
| EP-0237264-A2 | Process for preparing phosphonyloxyacyl amino acids and derivates thereof | E.R. Squibb & Sons, Inc. (US) | 1987-09-16 | — | — | EP | disclosed |
| US-4686298-A | Intermediates for alpha-acyloxy phosphonate angiotensin converting enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1987-08-11 | — | — | US | disclosed |
| CN-87100055-A | Orally active phosphonyl hydroxyacyl proline and preparation method thereof | — | 1987-08-05 | — | — | CN | disclosed |
| EP-0229520-A1 | Orally active phosphonyl hydroxyacyl prolines and processes for preparing phosphonyl hydroxyacyl prolines | E.R. Squibb & Sons, Inc. (US) | 1987-07-22 | — | — | EP | disclosed |
| US-4670422-A | HYPOTENSIVE AGENT, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4616005-A | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives | E. R. SQUIBB & SONS, INC. (US) | 1986-10-07 | — | — | US | disclosed |
| US-4076931-A | Derivatives of an antibiotic XK-62-2 and the process for the production thereof | ABBOTT LABORATORIES (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345411-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | ATP6V1B1, REN, NRDC | HTT 3641/4885FOLH1 4579/4885TGM2 2849/4885 |
| US-20120165283-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | ATP6V1B1, REN, NRDC | HTT 3641/4885FOLH1 4579/4885TGM2 2849/4885 |
| US-20160152653-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS | ATP6V1B1, REN, NRDC | HTT 3641/4885FOLH1 4579/4885TGM2 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.